AnGes マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Ei Yamada

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	22.2yrs
CEOの所有権	0.04%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	6.7yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Ei Yamada (74 yo)

22.2yrs

在職期間

Dr. Ei Yamada, Ph D., M.D., serves as Director at Emendo Bio, Inc. He has been the President and Chief Executive Officer of AnGes MG Inc since September 2002. Dr. Yamada has been the Chief Executive Office...

取締役

名称	ポジション	在職期間	報酬	所有権
Ei Yamada	CEO, President & Representative Director	23.3yrs	データなし	0.042% ¥ 5.7m
Naoya Sato	Director of Corporate Development & Director	2.7yrs	データなし	データなし
Makoto Hara	External Independent Director	6.7yrs	データなし	データなし
Junichi Komamura	External Independent Director	12.7yrs	データなし	データなし
Naoyuki Ono	Standing Corporate Auditor	3.4yrs	データなし	データなし
Norikazu Eiki	External Independent Director	10.5yrs	データなし	データなし
Kimiko Murofushi	External Independent Director	2.7yrs	データなし	データなし
Katsunori Horikoshi	Corporate Auditor	7.4yrs	データなし	データなし
Koichi Ando	Corporate Auditor	3.7yrs	データなし	データなし

6.7yrs

平均在職期間

73yo

平均年齢

経験豊富なボード: 4563の取締役会は経験豊富であると考えられます ( 6.7年の平均在任期間)。

AnGes マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

AnGes, Inc., Annual General Meeting, Mar 28, 2024

AnGes, Inc., Annual General Meeting, Mar 30, 2023

No independent directors

No independent directors

AnGes, Inc., Annual General Meeting, Mar 30, 2022

AnGes, Inc., Annual General Meeting, Mar 30, 2021

Recent updates

New major risk - Financial position

AnGes, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Second quarter 2024 earnings released: JP¥7.54 loss per share (vs JP¥10.25 loss in 2Q 2023)

New minor risk - Share price stability

AnGes, Inc. to Report Q2, 2024 Results on Aug 09, 2024

First quarter 2024 earnings released: JP¥9.14 loss per share (vs JP¥15.91 loss in 1Q 2023)

AnGes, Inc. to Report Q1, 2024 Results on May 10, 2024

AnGes, Inc. announced that it expects to receive ¥1.348415953 billion in funding from Cantor Fitzgerald Europe

New major risk - Share price stability

Full year 2023 earnings released: JP¥37.17 loss per share (vs JP¥94.29 loss in FY 2022)

AnGes, Inc., Annual General Meeting, Mar 28, 2024

Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy (Lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan

New minor risk - Market cap size

AnGes, Inc. to Report Fiscal Year 2023 Results on Feb 09, 2024

Vasomune Therapeutics, Inc. and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study

Vasomune Therapeutics, Inc. and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study

Third quarter 2023 earnings released: EPS: JP¥0.17 (vs JP¥18.09 loss in 3Q 2022)

Second quarter 2023 earnings released: JP¥10.25 loss per share (vs JP¥29.31 loss in 2Q 2022)

AnGes, Inc. announced that it has received ¥8.481467 million in funding from BofA Securities Japan Co., Ltd.

New major risk - Share price stability

AnGes, Inc. announced that it expects to receive ¥8.481467 million in funding

AnGes, Inc. to Report Q2, 2023 Results on Aug 09, 2023

First quarter 2023 earnings released: JP¥15.91 loss per share (vs JP¥19.19 loss in 1Q 2022)

Full year 2022 earnings released: JP¥94.29 loss per share (vs JP¥92.85 loss in FY 2021)

AnGes, Inc., Annual General Meeting, Mar 30, 2023

AnGes, Inc. to Report Fiscal Year 2022 Results on Feb 10, 2023

Third quarter 2022 earnings released: JP¥18.09 loss per share (vs JP¥29.39 loss in 3Q 2021)

No independent directors

Third quarter 2022 earnings released: JP¥18.09 loss per share (vs JP¥29.39 loss in 3Q 2021)

AnGes, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Second quarter 2022 earnings released: JP¥29.31 loss per share (vs JP¥27.72 loss in 2Q 2021)

AnGes, Inc. to Report Q2, 2022 Results on Aug 09, 2022

First quarter 2022 earnings released: JP¥19.19 loss per share (vs JP¥24.82 loss in 1Q 2021)

No independent directors

AnGes, Inc. to Report Q1, 2022 Results on May 10, 2022

AnGes, Inc., Annual General Meeting, Mar 30, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released: JP¥29.39 loss per share (vs JP¥10.39 loss in 3Q 2020)

Second quarter 2021 earnings released: JP¥27.72 loss per share (vs JP¥8.06 loss in 2Q 2020)

First quarter 2021 earnings released: JP¥24.82 loss per share (vs JP¥8.55 loss in 1Q 2020)

Full year 2020 earnings released: JP¥35.32 loss per share (vs JP¥35.81 loss in FY 2019)

AnGes, Inc. announced that it has received ¥98.2 million in funding from Cantor Fitzgerald & Co, Investment Arm

AnGes, Inc. announced that it expects to receive ¥98.2 million in funding from Cantor Fitzgerald & Co, Investment Arm

New 90-day low: JP¥1,156

AnGes, Inc., Annual General Meeting, Mar 30, 2021

Full year 2020 earnings released: JP¥35.32 loss per share (vs JP¥35.81 loss in FY 2019)

AnGes, Inc. to Report Fiscal Year 2020 Results on Feb 15, 2021

AnGes, Inc. (TSE:4563) completed the acquisition of Emendo Bio, Inc. from Orbimed Israel Partners II, L.P., OrbiMed Private Investments VI, LP, managed by OrbiMed Advisors LLC, Takeda Ventures, Inc. and others.

AnGes, Inc. and Er-Kim Enter into an Agreement for the Commercialization of Collategene® in Turkey

AnGes, Inc. to Report Q3, 2020 Results on Oct 26, 2020

CEO（最高経営責任者

在職期間

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14